Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) EBITDA Margin (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed EBITDA Margin for 14 consecutive years, with 19.07% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 403.0% year-over-year to 19.07%, compared with a TTM value of 16.99% through Dec 2025, up 255.0%, and an annual FY2025 reading of 16.99%, up 255.0% over the prior year.
  • EBITDA Margin was 19.07% for Q4 2025 at Neurocrine Biosciences, down from 26.44% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 280.0% in Q2 2021 and bottomed at 16.98% in Q1 2023.
  • Average EBITDA Margin over 4 years is 31.47%, with a median of 16.15% recorded in 2025.
  • The sharpest move saw EBITDA Margin skyrocketed 25169bps in 2021, then tumbled -1532bps in 2024.
  • Year by year, EBITDA Margin stood at 7.5% in 2021, then skyrocketed by 305bps to 30.36% in 2023, then crashed by -50bps to 15.04% in 2024, then grew by 27bps to 19.07% in 2025.
  • Business Quant data shows EBITDA Margin for NBIX at 19.07% in Q4 2025, 26.44% in Q3 2025, and 16.15% in Q2 2025.